Homocamptothecin

Drug Profile

Homocamptothecin

Latest Information Update: 04 May 2007

Price : $50

At a glance

  • Originator Biomeasure Inc; Institut de la Recherche sur le Cancer; Institut Henri Beaufour-Ipsen; Universite Libre de Bruxelles
  • Class Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Jul 1999 Preclinical development for Cancer in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top